News

Though popular weight loss jabs like Ozempic and Wegovy have been deemed safe and effective by the FDA, concerning side ...
Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...
For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with ...
A decision is expected in the fourth quarter of 2025.
Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...
Since its historic FDA approval in March 2024 as the first medication for the treatment of the prevalent liver disease ...
Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...
Ready to transform your body? It's possible with this program's personalized care, telehealth consultations, and semaglutide ...